Prediction of response to neoadjuvant hormonal therapy (NAHT) using upfront oncotype Dx recurrence score (RS): Results from the SAFIA phase III trial.

被引：0
|
作者：
Al-Saleh, Khalid A.
Bounedjar, Adda
Oukkal, Mohammed
Mahfouf, Hasen
Bouzid, Kamel
Bensalem, Assia
Fillali, Taha
Larbaoui, Blaha
Kandil, Alaa
Alfoheidi, Meteb
Errihani, Hassan
Ghosn, Marwan
Abdulaziz, Nashwa A.
Dabouz, Farida
Bahadoor, Mohun Ranvir K.
El Zawahry, Heba Mohamed
Kullab, Sherif A.
Nabholtz, Jean-Marc A.
机构：
[1] King Saud Univ, Coll Med, Riyadh, Saudi Arabia
[2] Anti Canc Ctr, Blida, Algeria
[3] CHU Beni Messous, Algiers, Algeria
[4] EHS ROUIBA, Algiers, Algeria
[5] CHU Constantine, Constantines, Algeria
[6] CHU Ibn Badis Constantine, Constantines, Algeria
[7] CAC Oran, Oran, Algeria
[8] Alexandria Univ Hosp, Alexandria, Egypt
[9] Prince Nora Canc Ctr, Jeddah, Saudi Arabia
[10] Natl Inst Oncol, Rabat, Morocco
[11] Hotel Dieu France Univ Hosp, Beirut, Lebanon
[12] ICRG, Sharjah, U Arab Emirates
[13] Ctr Jean Perrin, Clermont Ferrand, France
[14] NCI Cairo Univ, New Cairo, Egypt
[15] King Saud Univ Med City KSUMC, Riyadh, Saudi Arabia
[16] Jean Perrin Comprehens Canc Inst Auvergne, Clermont Ferrand, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
594
引用
收藏
页数：2
相关论文
共 14 条
  • [1] Response to Induction Neoadjuvant Hormonal Therapy Using Upfront 21-Gene Breast Recurrence Score Assay-Results From the SAFIA Phase III Trial
    AlSaleh, Khalid
    Al Zahwahry, Heba
    Bounedjar, Adda
    Oukkal, Mohammed
    Saadeddine, Ahmed
    Mahfouf, Hassen
    Bouzid, Kamel
    Bensalem, Assia
    Filali, Taha
    Abdel-Razeq, Hikmat
    Larbaoui, Blaha
    Kandil, Alaa
    Abulkhair, Omalkhair
    Al Foheidi, Meteb
    Errihani, Hassan
    Ghosn, Marwan
    Abdel-Aziz, Nashwa
    Arafah, Maria
    Boussen, Hamouda
    Dabouz, Farida
    Rasool, Haleem
    Bahadoor, Mohun
    Ayari, Jihen
    Kullab, Sharif
    Nabholtz, Jean-Marc
    JCO GLOBAL ONCOLOGY, 2021, 7 : 811 - 819
  • [2] Prediction of recurrence with the Oncotype DX recurrence score in node-positive, HR-positive, breast cancer patients treated with adjuvant chemotherapy: Results from PACS01 trial.
    Penault-Llorca, Frederique Madeleine
    Filleron, Thomas
    Asselain, Bernard
    Baehner, Frederick L.
    Fumoleau, Pierre
    Lacroix-Triki, Magali
    Butler, Steven M.
    Jamshidian, Farid
    Cherbavaz, Diana B.
    Shak, Steven
    Roca, Lise
    Sagan, Christine
    Lemonnier, J.
    Martin, Anne-Laure
    Roche, Henri Hubert
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] Correlation of Oncotype DX Recurrence Scores with Pathologic Response Following Neoadjuvant Ixabepilone and Cyclophosphamide in Patients with HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase II Trial.
    Yardley, D. A.
    Peacock, N. W.
    Hendricks, C.
    Huh, S. Y.
    Ketchum, S.
    Chao, C.
    Yoshizawa, C.
    Burris, H. A., III
    Hainsworth, J. D.
    CANCER RESEARCH, 2011, 71
  • [4] Using Oncotype DX Breast Recurrence Score® (RS) assay to define the role of neoadjuvant endocrine therapy (NET) in early-stage hormone receptor positive (HR plus ) breast cancer (BC)
    Taylor, Caitlin
    Foreman, Aimee
    Russell, Christy
    Bandyopdhyay, Dipankar
    Deng, Xiaoyan
    Floyd, Lisa
    Zelnak, Amelia
    O'Regan, Ruth
    Bear, Harry
    Meisel, Jane
    CANCER RESEARCH, 2022, 82 (04)
  • [5] Oncotype DX and proliferation response to short-term preoperative endocrine therapy for chemotherapy decision in early breast cancer: Biomarker data from the prospective multicenter phase II/III WSG-ADAPT trial.
    Gluz, Oleg
    Nitz, Ulrike
    Kates, Ronald
    Hofmann, Daniel
    Kuemmel, Sherko
    Nuding, Benno
    Schumacher, Claudia
    Aktas, Bahriye
    Forstbauer, Helmut
    Maass, Nicolai
    Braun, Michael Wilhelm
    Rezai, Mandi
    Kusche, Manfred
    von der Assen, Albert
    Shak, Steven
    Svedman, Christer
    Wuerstlein, Rachel
    Harbeck, Nadia
    Kreipe, Hans Heinrich
    Christgen, Matthias
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] DOES RESPONSE TO UPFRONT FOLFOX PREDICT EVENTUAL CLINICAL AND PATHOLOGICAL RESPONSE AFTER COMPLETION OF TOTAL NEOADJUVANT THERAPY FOR PATIENTS DIAGNOSED WITH RECTAL CANCER? OBSERVATIONS FROM A PHASE II CLINICAL TRIAL.
    Abdalla, A.
    Aref, A.
    Alame, A.
    Barawi, M.
    Ma, D.
    Szpunar, S.
    Kafri, Z.
    DISEASES OF THE COLON & RECTUM, 2020, 63 (06) : E150 - E151
  • [7] A phase II trial of neoadjuvant aromatase inhibitor therapy and the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancer and a low/intermediate risk Oncotype Dx Recurrence Score (≤5).
    Abu-Khalaf, Maysa M.
    Mougalian, Sarah Schellhorn
    Sanft, Tara Beth
    Hofstatter, Erin Wysong
    Chung, Gina G.
    Adelson, Kerin B.
    Silber, Andrea
    Brandt, Debra S.
    Bober-Sorcinelli, Kathleen E.
    Fishbach, Neal
    Kidwai, Wajih Zaheer
    Sabbath, Kert D.
    DiGiovanna, Michael
    Sikov, William M.
    Pusztai, Lajos
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: Results from the NeoALTTO phase III trial
    Sotiriou, Christos
    Rothe, Francoise
    Maetens, Marion
    Fumagalli, Debora
    Brown, David Norman
    Salgado, Roberto
    Bradbury, Ian
    Pusztai, Lajos
    Harbeck, Nadia
    Ignatiadis, Michail
    Sarp, Severine
    de la Pena, Lorena
    de Azambuja, Evandro
    Huober, Jens
    Nuciforo, Paolo
    Baselga, Jose
    Piccart, Martine
    Loi, Sherene
    Venet, David
    CANCER RESEARCH, 2018, 78 (04)
  • [9] TransNEOS: Validation of the oncotype DX recurrence score (RS) testing core needle biopsy samples from NEOS as predictor of clinical response to neoadjuvant endocrine therapy for postmenopausal estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer patients
    Yamamoto, Yutaka
    Iwata, Hiroji
    Masuda, Norikazu
    Fujisawa, Tomomi
    Toyama, Tatsuya
    Kashiwaba, Masahiro
    Ohtani, Shoichiro
    Taira, Naruto
    Sakai, Takehiko
    Hasegawa, Yoshie
    Nakamura, Rikiya
    Akabane, Hiromitsu
    Shibahara, Yukiko
    Sasano, Hiroshi
    Yamaguchi, Takuhiro
    Sakamaki, Kentaro
    Chao, Calvin
    McCullough, Debbie
    Sugiyama, Naoko
    Ohashi, Yasuo
    CANCER RESEARCH, 2018, 78 (04)
  • [10] Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial
    Venet, David
    Rediti, Mattia
    Maetens, Marion
    Fumagalli, Debora
    Brown, David N.
    Majjaj, Samira
    Salgado, Roberto
    Pusztai, Lajos
    Harbeck, Nadia
    El-Abed, Sarra
    Wang, Yingbo
    Saura, Cristina
    Gomez, Henry
    Semiglazov, Vladimir Fedorovich
    de Azambuja, Evandro
    Huober, Jens
    Nuciforo, Paolo
    Di Cosimo, Serena
    Piccart, Martine
    Loi, Sherene
    Rothe, Francoise
    Sotiriou, Christos
    CLINICAL CANCER RESEARCH, 2021, 27 (20) : 5607 - 5618
12